MorphoSys AG Reports Results For The First Quarter Of 2014
4/29/2014 9:31:32 AM
MARTINSRIED / MUNICH, Germany, April 29, 2014 (GLOBE NEWSWIRE) -- Conference call (in English) today at 2:00pm CEST (1:00pm BST/8:00am EDT)
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the three months ending 31 March 2014. Group revenues decreased by 6% to EUR 15.9 million compared to the same period of the previous year (Q1 2013: EUR 16.9 million). The reason for the revenue decrease was a one-time payment in Q1 2013 for a HuCAL license by Bio-Rad in connection with the sale of AbD Serotec. Earnings before interest and taxes (EBIT) were EUR 1.4 million (Q1 2013: EUR 2.5 million). On 31 March 2014, MorphoSys's cash, securities and interest-bearing assignable loans amounted to EUR 380.4 million (31 December 2013: EUR 390.7 million).
Help employers find you! Check out all the jobs and post your resume.
comments powered by